All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Identifying and managing ocular toxicities in patients with MM
Multiple myeloma (MM) is the second most prevalent hematologic cancer with a vast majority of patients requiring subsequent lines of therapy, leading to limited treatment options.
Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial
In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with NDMM eligible for transplant; Touzeau presented the...
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.